Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
|Slideshows|May 24, 2019
Our Top Stories in Rheumatology: Daily tofacitinib, pregnancy outcomes, pediatric lupus, RA risk and more
In this slideshow, we highlight the news you may have missed: Prescribing information for a newly approved treatment for pediatric lupus, new reports on negative pregnancy outcomes in PsA and ankylosing spondylitis, new information on the benefits of daily tofacitinib, and much more.
Advertisement
In this slideshow, we highlight the news you may have missed:Â Prescribing information for a newly approved treatment for pediatric lupus, new reports on negative pregnancy outcomes in PsA and ankylosing spondylitis, new information on the benefits of daily tofacitinib, and much more.
Advertisement
Related to this article
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.
A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.
Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.
Advertisement
Advertisement